Introduction
Although various chemotherapy regimens have been reported for use in patients with gastric cancer, the median prognosis for survival in patients with chemotherapy for advanced gastric cancer remains less than 9-12 months [1] . Given these conditions, we sought to develop a new active combination therapy regimen to prolong median survival, while also seeking a regimen that would be suitable for outpatient clinical use, in order to decrease time of hospitalization.
Paclitaxel (TXL) is thought to be an effective drug for gastric cancer, with reported response rates ranging from 20% to 28% in single-agent phase II studies [2] [3] [4] . In two of these studies, median survival times were 234 and 340 days, respectively, although more than 50% of the patients had previously received chemotherapy [3, 4] . Thus, it appears that TXL may prolong survival in gastric cancer patients.
Cisplatin (CDDP) is an active chemotherapeutic agent against gastric cancer. Treatment regimens including CDDP have shown high response rates [5] [6] [7] . CDDP has demonstrated synergism with variety of cytotoxic drugs, and synergism between TXL and CDDP has been established and reported [8, 9] .
Therapy combining CDDP and TXL has been reported in various regimens [10] [11] [12] [13] [14] . Most of these regimens consisted of administering 60 to 80 mg/m 2 of CDDP. However, patients receiving more than 50 mg/m 2 of CDDP may suffer nausea and vomiting [15] , and they would then need hydration to prevent CDDP renal toxicity. Thus, more than 50 mg/m 2 of CDDP is not suitable for outpatient clinical use.
We sought to confirm the efficacy and toxicity of combination therapy with TXL and a fixed-dose administration of 30 mg/m 2 CDDP. A biweekly regimen has been proposed to increase the dose intensity of TXL and to improve the ease of adoption for outpatient use. For this reason, we planned to evaluate biweekly TXL with a 30 mg/m 2 fixed-dose CDDP regimen.
Patients and methods

Patients
The objectives of this study were to determine the maximum tolerated dose (MTD) and to evaluate the toxicity and the preliminary activity of the above combination.
The criteria for eligibility included the following: (1) prior chemotherapy regimen completed 4 weeks before entry; (2) adequate bone marrow function (white blood cell [WBC] count ≥ 4000/mm 3 , platelet count ≥ 100 000/ mm 3 , hemoglobin ≥ 9.0 g/dl), adequate liver function (serum bilirubin level ≤ 1.5 mg/dl and serum transaminase level ≤ twice the upper limit of the normal range; if hepatic metastasis had been documented, then serum transaminase level ≤ three times normal range) and adequate renal function (serum creatinine level ≤ 1.5 mg/ dl, 24-h creatinine clearance ≥ 60 ml/min), normal electrocardiogram (ECG); (3) Eastern Clinical Oncology Group (ECOG) performance status (PS) of 2 or less; (4) age between 20 and 79 years; (5) absence of any other serious medical conditions; (6) absence of any other active malignancy; (7) life expectancy greater than 2 months.
Written informed consent was obtained from all patients prior to study entry. This study was approved by the Ethics Committees at the participating sites.
Treatment regimens
TXL infusions were administered on days 1 and 15, with a fixed 30 mg/m 2 dose of CDDP. To prevent hypersensitivity reactions, all patients were premedicated with 20 mg of dexamethasone intravenously, 50 mg of diphenhydramine orally, and 50 mg of ranitidine intravenously 1 h before TXL infusion. The starting dose of TXL was 100 mg/m 2 , and it was intravenously infused within 1 to 3 h before 1-to 3-h infusion of CDDP. The TXL dose then consisted of increments of 20 mg/m 2 until severe or life-threatening toxicities were observed. Patients were administered this regimen once every 2 weeks unless disease progress or intolerable toxicity was observed. If WBC counts fell below 3000/mm 3 or platelet counts fell below 75 000/mm 3 ; or if grade 3 or 4 nonhematological toxicity occurred; or if body temperature rose over 38°C or PS was over 3 immediately before administration, treatment was postponed.
For the first cycle of this therapy, the dose-limiting toxicity (DLT) was defined as National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3 or 4 neutropenia with infection or fever; or thrombocytopenia of 25 000/mm 3 or less; or NCI-CTC grade 3 or 4 nonhematological toxicity, except for anorexia, nausea/ vomiting, and alopecia. Treatment delay DLT was defined as treatment delay of 1 to 2 weeks for reasons of toxicity. The treatment dose at each level is summarized in Table 1 .
At least three patients were treated at each dose level. If none of the first three patients experienced DLT, escalation to the next TXL level was permitted. If one of three patients experienced a DLT, three other patients were enrolled at this level. Among the resulting six patients, if one or two experienced DLT, escalation was permitted; if more than two patients experienced DLT, that level was deemed the MTD. If two or three of three patients experienced DLT, that level was also considered the MTD. After confirmation of the MTD, the recommended dose (RD) for a phase II study was defined as one level below the MTD.
In the phase II part of the study, patients were not eligible if they had received chemotherapy that involved more than one regimen or contained platinum derivatives and/or taxane derivatives, or if they had suffered more than grade 2 peripheral neuropathy in prior chemotherapy. If the following adverse events had been observed during the previous treatment, the dose for the following treatment would be reduced by one level: hematological toxicity of at least grade 4; nonhematological toxicity of at least grade 3; peripheral neuropathy of at least grade 2. For other inclusion and exclusion criteria, treatment schedules were the same as for the phase I part of the study.
Response evaluation and toxicity
Patients were evaluated before entry into this study, to determine the extent of disease, by physical examination, chest X-ray, computed tomographic (CT) scan of 1  100  30  3  2  120  30  4  3  140  30  3  4  160  30  6  5  180  30  3 chest and abdomen, and endoscopic examination of the upper gastrointestinal tract. Complete blood cell counts, liver function test, renal function test, and urinalysis were assessed at least once every 2 weeks during treatment. CT scans were repeated as necessary to evaluate measurable lesions. NCI-CTC version 2 was applied to evaluate adverse drug reactions during the first and second cycles of treatment. The response criteria of the Japanese Research Society for Gastric Cancer [16] and the Response Evaluation Criteria in Solid Tumors Group criteria [17] were used to evaluate objective tumor response. In brief, the response criteria of the Japanese Research Society for Gastric Cancer define complete response (CR) as the complete disappearance of all measurable and evaluable lesions for a minimum of 4 weeks. A partial response (PR) is defined as a 50% or greater reduction in the sum of the products of the longest diameters of measurable lesions for a minimum of 4 weeks. Stable disease (SD) is defined as failure to observe a PR or CR and progressive disease for at least 4 weeks. Progressive disease (PD) is defined as a 25% or greater increase in the sum of the products of the longest perpendicular diameters of measurable lesions, or the appearance of new lesions. The response to primary tumors was assessed by the same Japanese criteria, based on roentgenographic and endoscopic findings.
Statistical considerations
The phase II part of this study was designed to test the null hypothesis that the true response probability is less than the not clinically significant level of 20%. The response rate was expected to be 40%. The probability of accepting the treatment with response probability (20%) is P = 0.05. The probability of rejecting the treatment with response probability (40%) is P = 0.10. Therefore, the sample size was 50 patients with P = 0.05; P = 0.1. After the enrollment of 20 patients, we planned to evaluate the toxicity, with the main point of the evaluation being suitability for an outpatient setting.
In the phase II part of the study, survival was calculated, from the date of treatment initiation, by the Kaplan-Meier method.
Results
Patient characteristics
In the phase I part of the study, 19 patients entered this trial between September 2001 and May 2003. Patient characteristics are summarized in Table 2 . All 19 patients were evaluated for toxicity, and 13 patients exhibited measurable lesions evaluable for response. The median age of the patients was 62 years (range, 50 to 78 years). Ten patients had gastric cancer as a primary lesion, while 8 patients had undergone surgical resection for primary gastric cancer. Six patients had an ECOG PS of 0, and 13 patients had an ECOG PS of 1. Histologically, 11 patients had intestinal-type adenocarcinoma, and 8 patients had the diffuse type. All patients had metastatic lesions. The metastatic sites were the lung in 1 patient, the liver in 6, the lymph nodes in 7, and the peritoneum in 8. Fourteen patients had received prior chemotherapy; 13 patients had received S-1 alone, and 1 had received S-1 plus CDDP. All prior chemotherapy was completed 4 or more weeks before entry: 5 patients were prior chemotherapy-naïve.
In the phase II part of the study, 21 patients entered between July 2003 and May 2004. One patient refused to receive the treatment regimen after the first administration, and this patient was excluded from analysis. Characteristics of the phase II patients are summarized in Table 2 . In an interim analysis of safety, our group decided to cease continuing this part of the study because of the high proportion of dose reductions and treatments delays within the first cycle.
The median age of the patients was 60 years (range, 45 to 76 years). Eight patients had gastric cancer as a primary lesion, and 12 patients had undergone surgical resection for primary gastric cancer. Eleven patients had an ECOG PS of 0, 8 had an ECOG PS of 1, and 1 had an ECOG PS of 2. Histologically, 7 patients had intestinaltype adenocarcinoma, and 13 had the diffuse type. All patients had metastatic lesions. The metastatic sites were the lymph node in 15 patients; liver in 15; peritoneum in 4; and bone, ovary, and esophagus in 1 patient each. Sixteen patients had received chemotherapy; 11 had received T-S1 alone, 1 had received S-1 plus irinotecan (CPT-11), 1 had received T-S1 plus CDDP, 1 had received methotrexate plus 5-fluorouracil (5FU), 1 had received uracil/tegafur (UFT), and 1 had received mitomycin C as intraarterial chemotherapy for liver metastasis. All prior chemotherapy was completed 4 or more weeks before entry: 4 patients were chemotherapy-naive (3 had had adjuvant chemotherapy only).
Determination of MTD in the phase I part of the study
In the phase I part of the study, all patients were evaluable for adverse reactions, and 18 patients completed one or more cycles of treatment. At levels 1 and 2, one patient exhibited grade 4 neutropenia during the first cycle. At level 4, one of the first three patients exhibited grade 4 febrile neutropenia, while three other patients were enrolled to this level. At level 5, one patient exhibited grade 3 motor neuropathy, while one exhibited grade 3 myalgia with grade 3 dyspnea. We therefore determined dose level 5, which represented a TXL dose of 180 mg/m 2 , with CDDP 30 mg/m 2 , to be the MTD, and the RD to be level 4, with a TXL dose of 160 mg/m 2 plus CDDP 30 mg/m 2 . The most common adverse reactions in the phase I part of the study are summarized in Table 3 .
Safety
All 20 patients enrolled in the phase II part of the study were assessable for safety, and received a total of 48.5 cycles. The median number of cycles was 2. In these 20 patients, treatment delay, dose reduction, or both, occurred in 6, 2, and 3 patients, respectively, within 1 cycle (a total of 11 patients could not be administered the RD) and all of the dose reductions and treatment delays were due to a decrease in the WBC count or delay in recovery of neutropenia. For the phase II part of the study, the overall numbers of hematological and nonhematological toxicities are listed in Table 3 . Grade 3 or 4 neutropenia was the most common adverse event and occurred in 65% of the patients. During treatment, 25% of the patients received granulocyte colony-stimulating factor (G-CSF), but no patients had febrile neutropenia. Major nonhematological toxicities were nausea/vomiting, anorexia, fatigue, alopecia, and sensory neuropathy. Two patients showed adverse reactions of grade 3 or 4. One patient had anorexia (5%) and other had sensory neuropathy (5%). None of the patients had an increase of serum creatinine of more than grade 3 within two cycles.
Efficacy
In the phase I part of the study, 4 of the 19 patients showed no measurable lesions, while 2 patients discontinued the protocol due to DLT, all 6 being determined as not evaluable (NE). The remaining 13 patients were evaluable for efficacy. This group included 6 patients with a PR, 4 with SD, and 3 with PD, yielding a response rate of 46.1% in the evaluable patients (6 of 13 patients). The response rates in the evaluable patients with intestinal-type adenocarcinoma and diffuse-type adenocarcinoma were 50% (4/8) and 40% (2/5), respectively. The response rate of the evaluable patients with prior chemotherapy was 55.5% (5/9). The response rate of the evaluable patients without prior chemotherapy was 25% (1/4). (Table 4 ).
In the phase II part of the study, a total of 20 patients were evaluated to determine the response rate at the RD. The overall response rate was 25.0%; 5 patients had PR as the best response, 7 had SD, 6 had PD, and 2 were defined as not evaluable (NE). Subgroup analysis by pathological type for the 20 patients showed that the response rates were 28.6% (2/7) for those with intestinal-type adenocarcinoma who were evaluable and 23.1% (3/13) for evaluable patients with the diffuse type. Subgroup analysis by prior chemotherapy for the 20 patients showed that the response rate was 25.0% (4/16) for the evaluable patients with prior chemotherapy and 25.0% (1/4) for those without prior chemotherapy (Table 4) .
The median survival time was 272 days and the 1-year survival rate was 30% (Fig. 1) .
Determination of MTD in the phase II part of the study
As mentioned above, 11 of the 20 patients (55% of the study subjects) could not be administered the RD on a biweekly schedule, so we decided on a new RD, as one level under the previous RD, which represented a TXL dose of 140 mg/m 2 with CDDP 30 mg/m 2 . At this new RD, we are now performing a new phase II study to check the efficacy and feasibility of the regimen.
Discussion
This study determined the MTD and RD, and also evaluated the preliminary toxicity and activity of TXL with fixed doses of CDDP for advanced gastric cancer. TXL is a promising drug for use in combination with CDDP, and there are several phase I reports of combination chemotherapy involving TXL and CDDP. These two drugs have different mechanisms of action and fewer overlapping toxicities than other combinations, without neurotoxicity. When TXL was administered in combination with CDDP, treatment was sometimes delayed by the resulting neurotoxicity. When TXL administered every 3 weeks was compared to weekly TXL, the toxicity profile was better tolerated (particularly with respect to myelosuppression and peripheral neuropathy) at the weekly schedule, while efficacy remained almost unchanged [18] . This result shows that divided administrations of TXL may reduce myelosuppression and neuropathy. Before increasing dose-intensity, we Although high doses of CDDP are often used in combination regimens for gastric cancer, the efficacy of high doses is still open for debate. We set the CDDP dose at 30 mg/m 2 (because high doses of CDDP add to toxicity and require intense intravenous hydration to protect against renal toxicity) to develop a well-tolerated regimen ideal for the outpatient setting.
Compared with the results of a phase II study of a TXL-containing regimen for gastric cancer, our regimen was less toxic than the triweekly administration of TXL in that study [2] [3] [4] , with especially notable reduced risks of grade 3 or 4 neutropenia and neuropathy. Kornek et al. [19] reported a phase II study of a biweekly schedule of combination therapy with 160 mg/m 2 TXL and 60 mg/m 2 CDDP in gastric cancer patients, with the regimen being based on a phase I study reported by van der Gaast et al. [14] . In the report of Kornek et al. [19] , the regimen offered promising therapeutic activity, with a response rate of 44% among patients who had not undergone previous chemotherapy. However, 73% of their patients received G-CSF, 49% suffered peripheral neuropathy, and 11% developed documented infections though G-CSF support. An important issue in patients with gastric cancer is toxicity. The elderly or poor-performance-status patient population cannot tolerate aggressive regimens such as those with high doses of CDDP. Because treatment regimens with G-CSF support are still under consideration [20] , In the present study, we developed a treatment regimen without fluoropyrimidine for advanced gastric cancer. As most of the regimens that are expected to be first-line therapy contain fluoropyrimidines to prolong survival, treatments for fluoropyrimidine-resistant gastric cancer are necessary as second-line therapy. TXL is a good candidate for this situation because of its lack of cross-resistance to fluoropyrimidine. In the phase II part of the present study, about 75% of the patients had received a fluoropyrimidine-based regimen as first-line therapy. We found a response rate of 25.0% in the phase II part of the study, although more than 50% of the patients could not receive the RD on the biweekly schedule.
In our determination of the new RD, we discussed a dose reduction of the RD in the interim analysis, in which treatment delay and dose reduction had occurred in a total of 11 patients within one cycle on the enrollment of 20 patients in the phase II part of the study. Based on the phase I part of the study, we discussed that we should reduce the dose of TXL and start a new phase II study at the TXL dose of 140 mg/m 2 . The outcome will depend on the point of whether efficacy can be observed at dose level one or dose level two (level 1 showed two PRs and one SD, while level 2 showed two PRs and two SDs) and whether these treatments could be continued until disease progression (data not shown) in the phase I part. Our initial concept was to develop a new treatment option which has good feasibility within the outpatient setting.
To determine the optimal RD is sometimes very difficult in a phase I study. The IFL regimen (irinotecan, 5FU, and leucovorin combination regimen) is a good example of such a difficulty. A phase I study of the IFL regimen was first reported by Saltz et al. [21] , and after a phase III study [22] , this regimen showed a high mortality rate within 60 days, and a new RD was decided upon as a modified IFL regimen. In the light of this example, we decided to decrease the TXL dose to one level below that in the phase I part of the present study.
Finally, we decided to reduce the dose of TXL from 160 mg/m 2 to 140 mg/m 2 . We are now conducting a phase II study at the new RD to evaluate the efficacy and longterm feasibility of the regimen, particularly with respect to peripheral neuropathy, a characteristic side effect of TXL administration.
In conclusion, with regard to the TXL-plus-CDDP combination in our study: (1) the recommended dose was determined to be TXL 140 mg/m 2 with CDDP 30 mg/m 2 ; and (2) we found that this regimen showed modest efficacy and a safe toxicity profile so that it could be offered as a candidate component of standard regimens for treating gastric cancer. We are now performing another phase II study, with the KoreaJapan Collaborative Study Group, to confirm the efficacy and feasibility of TXL 140 mg/m 2 with CDDP 30 mg/m 2 .
